期刊文献+

抗ErbB2嵌合抗体chA21对SKBR3细胞的增殖抑制以及对PI3K/Akt和Erk1/2信号转导途径的影响 被引量:3

Anti-proliferation role and effect on PI3K/Akt and Erk1/2 signal pathways of a chimeric anti-erbB2 antibody(chA21)on SKBR3 cells
下载PDF
导出
摘要 目的检测抗ErbB2嵌合抗体chA21对高表达ErbB2乳腺癌细胞SKBR3的增殖抑制作用,并分析抗体对细胞膜上ErbB2分布以及对细胞PI3K/Akt和Erk1/2信号转导途径的影响,探讨chA21的抑癌机制。方法采用MTT检测chA21对SKBR3的增殖抑制作用,流式细胞术检测经chA21处理后细胞膜上ErbB2抗原的分布变化,Western blot检测抗体作用后对细胞PI3K/Akt和Erk1/2信号转导途径的影响。结果chA21可抑制SKBR3细胞的增殖,其作用呈剂量和时间依赖性。抗体作用后可下调细胞膜上ErbB2含量,并不同程度下调细胞的PI3K/Akt和Erk1/2的活化水平。结论chA21可抑制SKBR3细胞增殖,可能通过下调细胞膜上ErbB2分布而减少其介导的PI3K/Akt和Erk1/2信号转导途径的活化来实现的。 Aim To study the inhibitory effect of anti-ErbB2 chimeric antibody chA21 on proliferation of human malignant breast cancer cell lines SKBR3 and explore its possible mechanisms through studying its effects on ErbB2 distribution and PI3K/Akt,Erk1/2 signal transduction.Methods The inhibitory effect of chA21 on SKBR3 was assessed by MTT assay.The effect of chA21 on distribution of ErbB2 on cell plasma membrane was determined by FACS(Fluorescence-activated cell sorting)analysis;p-Akt and p-Erk1/2 were detected by Western blot.Results The inhibitory rate of chA21 on SKBR3 cells in vitro increased in a dose and time dependent manner.Furthermore,it could down-regulate the distribution of ErbB2 on plasma membrane and decrease the activation of p-Akt and p-Erk1/2.Conclusions ChA21 can inhibit the proliferation of SKBR3 cell in vitro.Down-regulation ErbB2 on cell plasma membrane resulting in decreasing the activation of p-Akt and p-Erk1/2 may be one of the mechanisms of the inhibitory effect.
出处 《中国药理学通报》 CAS CSCD 北大核心 2009年第11期1442-1445,共4页 Chinese Pharmacological Bulletin
基金 国家自然科学基金资助项目(No30570362) 安徽省自然科学基金资助项目(No90413140) 高校安徽省级优秀青年人才基金资助项目(No2009SQRZ043) 安徽省高校青年教师科研资助项目(No2008jq1067) 安徽医科大学校科研基金资助课题(No2007kjzj02 2008kj05)
关键词 乳腺癌 SKBR3 ERBB2 嵌合抗体 PI3K/AKT ERK1/2 信号转导 breast cancer SKBR3 ErbB2 chimeric antibody PI3K/Akt Erk1/2 signal transduction
  • 相关文献

参考文献4

二级参考文献43

  • 1薛花,吴强,胡向阳,凌晓光,程联胜,刘兢,刘爱萍.抗HER-2嵌合抗体chA21对SKOV3细胞增殖的抑制及诱导其凋亡的作用[J].细胞与分子免疫学杂志,2006,22(1):51-53. 被引量:2
  • 2凌晓光,吴强,薛花,杨枫,程联胜,刘兢.抗HER-2工程抗体chA21和Herceptin对人卵巢癌SKOV3裸小鼠移植瘤的抑制作用[J].西安交通大学学报(医学版),2006,27(2):109-112. 被引量:3
  • 3凌晓光,吴强,薛花,杨枫,程联胜,刘兢.抗HER-2抗体诱导人卵巢癌裸小鼠移植瘤细胞凋亡及其对凋亡相关蛋白表达的影响[J].临床与实验病理学杂志,2006,22(2):218-222. 被引量:5
  • 4Parsons R. Human cancer, PTEN and the PI-3 kinase pathway[J].Semin Cell Dev Biol,2004,15(2):171-6.
  • 5Lee J, Yang HJ, Georgescu MM et al. Crystal structure of the PTEN tumor suppressor implications for its phosphoinositide phosphatase activity and membrane association[J].Cell,1999, 99(3):323-34.
  • 6Leslie NR, Gray A, Pass I et al.Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signaling pathways downstream of phosphoinositide 3-kinase[J].Biochem J,2000,346(Pt3):827-33.
  • 7Yamada KM, Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis[J].J Cell Sci,2001,114(13):2375-82.
  • 8Giri D, Ittmann M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma[J].Hum Pathol, 1999,30(4):419-24.
  • 9Leslie NR, Bennett D, Gray A et al. Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions[J].Biochem J,2001,357(Pt2):427-35.
  • 10Patel L, Pass I, Coxon P et al. Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN[J].Curr Biol,2001,11(10):764-8.

共引文献41

同被引文献36

  • 1沈震宇,薛花,程联胜,吴强,刘兢,杨枫.p185高表达人卵巢癌裸鼠模型的建立[J].安徽医科大学学报,2005,40(4):300-301. 被引量:2
  • 2Burstein H J.The distinctive nature of HER2-positive breast cancers[J].N Engl J Med,2005,353(16):1652-4.
  • 3Nahta R,Yu D,Hung M C,et al.Mechanisms of disease:understanding resistance to HER2-targeted therapy in human breast cancer[J].Nat Clin Pract Oncol,2006,3(5):269-80.
  • 4Cho H S,Mason K,Ramyar K X,et al.Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab[J].Nature,2003,421(6924):756-60.
  • 5Nagy P,Friedlander E,Tanner M,et al.Decreased accessibility and lack of activation of ErbB2 in JIMT-1,a herceptin-resistant,MUC4-expressing breast cancer cell line[J].Cancer Res,2005,65(2):473-82.
  • 6Kobayashi S,Boggon T J,Dayaram T,et al.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2005,352(8):786-92.
  • 7Stephens P,Hunter C,Bignell G,et al.Lung cancer:intragenic ERBB2 kinase mutations in tumours[J].Nature,2004,431(7008):525-6.
  • 8Lee J W,Soung Y H,Seo S H,et al.Somatic mutations of ERBB2 kinase domain in gastric,colorectal,and breast carcinomas[J].Clin Cancer Res,2006,12(1):57-61.
  • 9Longva K E,Pedersen N M,Haslekas C,et al.Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2[J].Int J Cancer,2005,116(3):359-67.
  • 10Gennari R,Menard S,Fagnoni F,et al.Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2[J].Clin Cancer Res,2004,10(17):5650-5.

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部